Trial Profile
Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Stereotactic Body Radiation Therapy and Intermittent Androgen Deprivation Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Nelitolimod (Primary) ; Pembrolizumab (Primary) ; Abiraterone acetate; Leuprorelin; Prednisone
- Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2024.
- 12 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.
- 20 Sep 2022 Planned End Date changed from 31 Mar 2023 to 31 Oct 2023.